California Institute of Technology

Johns Hopkins University

The Brigham and Women's Hospital, Inc.

Children's Hospital Los Angeles

David J Anderson

Hai U Wang

Zhoufeng Chen

Derek L Stemple

Lukas Sommer

Xinzhong Dong

Qiufu Ma

Christopher J Schoenherr

Moriel Zelikowsky

Andrea Choe

Melvin I Simon

Mark Zylka

Donghun Shin

Sang-kyou Han

Pietro Perona

Michael A Gimbrone, Jr

Sean J Morrison

Barbara J Wold

Marie E Csete

Guillermo Garcia-Cardena

Qiao Zhou

Todd E Anthony

Qiufa Ma

Ben Deneen

Hae-Ri Song

Weizhe Hong

Qin Liu

Li-Ching Lo

Quifa Ma

Nirao M Shah

In some embodiments, methods of inhibiting, ameliorating, reducing the severity of, treating, reducing the likelihood of, or preventing social isolation stress or symptoms thereof in a subject in need thereof are described. In some embodiments, methods of determining a risk of social isolation stress in a subject are described.

Neurokinin antagonists and uses thereof

Methods of expressing a neuropeptide in a neuron of a subject are described. Methods of altering a behavior in a subject in need thereof are described. Kits are described. Vectors are described.

Expression of neuropeptides

According to some embodiments herein, expression systems and methods for activity-dependent transcription of nucleic acids are provided. In some embodiments, adeno-associated viral vector systems comprise an immediate early gene promoter operably linked to a transcriptional activator. The transcription activator can be fused to an N-terminal portion of an immediate early gene, for example fos.

Activity-dependent expression of nucleic acids

Systems and methods for performing behavioral detection using three-dimensional tracking and machine learning in accordance with various embodiments of the invention are disclosed. One embodiment of the invention involves a the classification application that directs a microprocessor to: identify at least a primary subject interacting with a secondary subject within a sequence of frames of image data including depth information; determine poses of the subjects; extract a set of parameters describing the poses and movement of at least the primary and secondary subjects; and detect a social behavior performed by at least the primary subject and involving at least the second subject using a classifier trained to discriminate between a plurality of social behaviors based upon the set of parameters describing poses and movement.

Systems and methods for behavior detection using 3D tracking and machine learning

The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents.

Methods and compositions for treating or preventing pruritis

The invention relates generally to novel genes expressed in normal but not Neurogenin-1-deficient animals. The invention relates specifically to a novel family of G protein-coupled receptors and a novel family of two-transmembrane segment proteins that are expressed in dorsal root ganglia, and a method of screening for genes specifically expressed in nociceptive sensory neurons.

Pain signaling molecules

The invention relates to novel neurogenin proteins, nucleic acids and antibodies.

Neurogenin

Disclosed herein are compositions comprising NFIA inhibitors, as well as methods of using the same to treat glioma and astrocytomas.

NFIA in glial fate determination, glioma therapy and astrocytoma treatment

Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.

Artery- and vein-specific proteins and uses therefor

Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.

The invention relates to methods and reagents for promoting the differentiation of oligodendrocytes from stem cells, by co-activating the Olig genes and the Nkx2.2 genes, and the use of the differentiated oligodendrocytes thus obtained in treating diseases, such as Multiple Sclerosis (MS). The invention also relates to the use of OLPs and oligodendrocytes thus obtained for drug screening.

Oligodendrocyte determination genes and uses thereof

Growing community of inventors

Altadena, CA, United States of America

David J Anderson